Frequently Asked Questions
The global Hemophilia market is expected to be impacted significantly by COVID-19.
North America accounted for the highest share in the global Hemophilia market in terms of Value.
The increasing prevalence and severity of bleeding illnesses due to genetic evolution are predicted to drive overall market growth. The increase in R&D studies for treatment treatments in the segment, as well as the increase in the target population, diagnosis rate, and use of hemophilia preventive therapy, all contribute to the expansion of the hemophilia treatment market.
Hemophilia A segment had a significant share in 2021 with more than 40% of the market revenue share.
The prophylaxis segment had a significant share in 2021, with more than 60% of the market revenue share.